Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Debio 0932 is an orally active inhibitor of HSP90 (IC50s: 100 and 103 nM for HSP90α and HSP90β, respectively).
ターゲット&IC50 | HSP90 β:103 nM, HSP90 α:100 nM |
In vivo | Debio 0932 is capable of penetrating the blood-brain barrier and demonstrates favorable pharmacokinetic properties in tumor-bearing nude mice at a dosage of 30 mg/kg orally. At 80 mg/kg orally, it significantly reduces symptoms of psoriasis by day 11 and lessens epidermal thickness in a psoriasis xenograft transplantation model [2]. Furthermore, a dose of 160 mg/kg orally leads to the degradation of HSP90 client proteins, inhibiting tumor growth and extending survival in various U87MG glioblastoma animal models. This dosage also enhances antitumor effects in an erlotinib-resistant H1975 subcutaneous tumor model. Dose-dependent suppression of tumor growth in the U87MG subcutaneous (s.c.) tumor model is observed with oral doses of 40, 80, or 160 mg/kg administered every other day (q2d) [1]. Additionally, oral doses of 80, 120, and 160 mg/kg exhibit a dose-dependent reduction of tumor growth in the H1975 subcutaneous tumor model [3]. |
別名 | CUDC-305 |
分子量 | 442.58 |
分子式 | C22H30N6O2S |
CAS No. | 1061318-81-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 33 mg/mL (74.56 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Debio 0932 1061318-81-7 Cytoskeletal Signaling Metabolism HSP CUDC 305 CUDC-305 CUDC305 Inhibitor inhibitor inhibit